Hi all
Below information gained from Ai.
The European Medicines Agency (EMA) offers several key benefits to small and medium-sized enterprises (SMEs) in the pharmaceutical sector that obtain SME status:
Financial incentives:
SMEs receive significant fee reductions or exemptions for regulatory procedures, including:90-100% fee reduction for scientific advice
Fee deferrals for marketing authorization applications40-100% fee reductions for post-authorization activities 90% fee reduction for inspections Regulatory support
The EMA provides guidance, advice and assistance to SMEs throughout the drug development and approval process.
Translation assistance: Free translations of product information into all EU languages for initial marketing authorizations.
Scientific advice: Discounted fees for scientific advice to help optimize development plans.
Increased visibility: Inclusion in EMA's public SME register to facilitate networking and partnerships.
Administrative support: 100% fee reduction for certain administrative services.
Pharmacovigilance incentives: Fee exemptions or reductions for pharmacovigilance activities.
These benefits aim to support innovation by reducing financial and regulatory burdens on smaller companies.
To be eligible, companies must be established in the EU/EEA, meet SME criteria, and apply for SME status with the EMA.
Overall, the SME initiatives help smaller pharmaceutical companies navigate the complex EU regulatory landscape and bring new medicines to market more efficiently.
Another Ace on the table.
Very well done Management team.
i would love to corner the Japanese market, give it time. That is a hard nut to crack.
Kpax
- Forums
- ASX - By Stock
- PAA
- Ann: PharmAust Granted SME Status by European Medicines Agency
Ann: PharmAust Granted SME Status by European Medicines Agency, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.77M |
Open | High | Low | Value | Volume |
19.5¢ | 20.0¢ | 19.5¢ | $28.93K | 148.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 213419 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 47368 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 213419 | 0.190 |
12 | 561555 | 0.185 |
19 | 557518 | 0.180 |
9 | 736100 | 0.175 |
9 | 217553 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 47368 | 1 |
0.200 | 197665 | 4 |
0.205 | 203779 | 7 |
0.210 | 327156 | 3 |
0.215 | 388143 | 6 |
Last trade - 11.46am 01/07/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online